Shares of radiopharmaceutical company Point Biopharma (NASDAQ:PNT) are seeing major price action coupled with rising trading volume as the stock has scored five Buy ratings in the past seven days.
While the stock remains volatile, the average volume over the past 10 days was about 1.61 million versus a trading volume of 843,300 shares in the past three months.
Impressively, all of the recent five Buy ratings from analysts also come with price targets that imply a triple-digit upside potential in the stock.
Most recently, Truist Financial analyst Nicole Germino has initiated coverage on the stock with a Buy rating and a $22 price target that implies a 145.81% potential upside.
What Is the Price Target of PNT?
Overall, the Street has a Strong Buy consensus rating on PNT alongside an average price target of $20.83. This indicates a massive 131.70% potential upside in the stock.
Earlier this week, the company announced a public offering of 13.9 million shares at $9 per share. The offer is expected to close today.
Read full Disclosure
